Lupin carves-out its LupinLife Consumer Healthcare
Lupin announced the strategic carve-out of its consumer healthcare business, LupinLife Consumer Healthcare (LCH), into a wholly owned subsidiary, effective 01 July 2025. This initiative aligns with the aspiration to establish a specialized consumer healthcare entity, with an enhanced focus on India's rapidly growing self care market.
Since its inception in 2017, LupinLife Consumer Healthcare has emerged as a strong over-the-counter (OTC) healthcare business with a portfolio of scientifically formulated and trusted brands such as Softovac, Beplex Forte, Corcium and Aptivate. Anil Kaushal will lead the new independent entity as Chief Executive Officer. This restructuring will enable enhanced focus with targeted investments, leading to increased consumer impact, market expansion, and accelerated growth.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
32 minutes ago
- Business Standard
Lupin launches nasal spray in US, part of 200-drug pipeline by FY30
Indian pharmaceutical major Lupin on Thursday announced the launch of a new nasal spray — Ipratropium Bromide Nasal Solution — in the United States market. The product is available in two strengths: 0.03 per cent and 0.06 per cent. The company stated that the spray is used to treat runny nose (rhinorrhoea) caused by allergies, the common cold or other non-allergic conditions. It is suitable for both adults and children, depending on the prescribed strength. The product is the generic version of a nasal spray called Atrovent, which is already available in the US market. The spray is considered bioequivalent, meaning it acts in the same way in the body as the reference drug. Lupin has a strong presence in the US and European pharmaceutical markets. As reported by Business Standard in May, the company is targeting a greater share of revenue from its complex generics portfolio in the US and Europe. With a pipeline of over 200 products over the next five years, Lupin expects the revenue share from complex generics to reach 62 per cent by FY30. The contribution from such products is projected at 21 per cent by FY26. Complex generics include high-value products such as inhalers, injectables, transdermal patches and ophthalmic solutions, which typically contain more sophisticated active ingredients and delivery mechanisms. Generic drugs are copies of branded medicines that have gone off-patent. Complex generics differ from simple generics in terms of formulation, technology and margin potential. On Friday, Lupin's shares closed at ₹1,978 on the Bombay Stock Exchange, up ₹22.40 or 1.15 per cent.
Business Standard
an hour ago
- Business Standard
Lupin launches generic version of anticholinergic medication Ipratropium bromide in United States
Lupin has announced the launch of Ipratropium Bromide Nasal Solution (nasal spray) in two strengths in the United States. Ipratropium Bromide Nasal Solution is a bioequivalent to Atrovent Nasal Sprayof Boehringer Ingelheim Pharmaceuticals, Inc. The solution is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older. According to IQVIA MAT May 2025, Ipratropium Bromide Nasal Solution (RLD Atrovent) had estimated annual sales of $63 million in the U.S. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The companys consolidated net profit surged 114.9% to Rs 772.52 crore on a 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24. The scrip added 1.36% to end at Rs 1982.20 on the BSE today.
Time of India
15 hours ago
- Time of India
After Nagpur, Ranchi to get AC electric buses soon: Union min
1 2 3 Ranchi: The long awaited Ratu road flyover was inaugurated by Union minister of road transport and highways Nitin Gadkari on Thursday. The 4.18 km long, four-lane project has been built at a cost of Rs 560 crore. Once opened for traffic movement, the flyover will boost the city traffic by doing away with the perennial traffic congestion at Ratu road. Besides inaugurating the flyover, Gadkari also laid the foundation stone for two new flyover projects at the OTC ground in the evening. Various MPs, state transport minister Deepak Birua among others were present on the occasion. Calling the newly opened flyover a symbol of the city's rapid urban development, Gadkari assured continued support from the Centre for fulfilling key regional demands. Responding positively to local MP and union minister of state for defence, Sanjay Seth's four-point demand, Gadkari made a slew of announcements focused on connectivity, culture, clean transport, and agriculture. Seth highlighted the need for an Outer Ring Road to decongest Ranchi further, which Gadkari approved in principle. "We have granted permission for preparing the detailed project report (DPR) for a Rs 6,000 crore Outer Ring Road project. Once ready, work will begin on priority," Gadkari announced. Gadkari also asked Seth to send a proposal for beautification of the flyover using local art forms. Seth also demanded the widening of the Ranchi-Angada-Silli-Muri road, which the minister assured would be considered under future expansion plans. Gadkari also announced that Ranchi could be the second city after Nagpur to run AC electric flash line buses in future if all goes well, promising a 30% reduction in air pollution compared to diesel-run public transport. He however did not elaborate further on the project. The Ratu road flyover, which begins near Naga Baba Khatal, descends towards Itki Road on one side and OTC Ground on the other. Built by the National Highway Authority of India, construction for the project started in 2022.
